Look at TSMY getting vaccinated. The medical officer was wearing gloves or not?

Harta RM1 billion net profit last quarter
Supermax RM1 billion net profit last quarter
Glove ASP continue to rise

Glove counters will win


other news, EPF had a hand in shorting Top Glove?
https://www.theedgemarkets.com/article/frankly-speaking-questionable-move

Bursabets today. Let's go!

From CIMB report on HARTA
TP 21.80 (CP 12.62)
High profit because of high ASP
higher profits in future from even higher ASP

Investors will win the glove game
traders will depend on luck

New Covid strain detected in UK. countries are banning flights from UK

https://www.thestar.com.my/news/world/2020/12/20/covid-19-countries-ban-uk-flights-as-britain-says-new-virus-strain-039out-of-control039

On TOPGLOV. last price RM7.01

Public Bank: BUY. TP 9.70
Kenanga: BUY. TP 10.68
AmInvest: HOLD. TP 7.07

What happens to TG will happen to other glove counters

https://klse.i3investor.com/servlets/ptres/58118.jsp
https://klse.i3investor.com/servlets/ptres/58117.jsp
https://klse.i3investor.com/servlets/ptres/58115.jsp

Tomorrow Top Glove expected QR. Expected to post record breaking profits of at least RM2 Bililion. Hopefully this will improve the sentiments that regardless of vaccine news, gloves are still the biggest money makers

https://www.theedgemarkets.com/article/top-gloves-next-recordbreaking-quarterly-profit-expected-surge-past-rm2b

Top glove QR expected this week. Good results will increase sentiment about gloves. There's no reason TG won't report another highly profitable quarter

Bursa is a weird place

Companies who only announced they want to start make gloves: shares go up

Established companies who can make billions of gloves per year, who will have high demand until 2022, make tens or hundreds of millions in profits: Shares go down

Careplus CEO and wife just bought additional 389,600 shares on top of the 400,000 shares they bought in early november

Do you think he would invest if he doesn't think the price will go up?

Top Glove1QFY2021 QR scheduled to be out on 9th December 2020. With each strong QR from every glove company, the market will realise that despite all the vaccine hype, gloves companies are making a ton of cash.

QRs after vaccine has been discovered will also show strong profits due to gloves being required to administer the vaccine

If you want a low risk investment with a huge probability to profit, gloves and PPE counters are the way to go

Careplus CEO and wife bought 400k of careplus shares. Top Glove bought back shares, EPF buying Harta shares

Smart people know where the money is going.

Top Glove QR expected to come out on Dec 9. High profits reported despite vaccine news will push glove counter prices higher and prove the 'vaccine is bad news for gloves' theory wrong.

Rubberex QR proves to everyone, especially vaccine lovers that despite all the vaccine news, gloves will be in strong demand.

No vaccine: Good news for gloves
Vaccine: Good news for gloves

Thank you RHB for knocking some sense into people.

Company CEO & director Lim Kwee Shyan and his wife Ng Shu Si bought 400k shares of careplus.

According to the M+ app, this news was released at 5.21pm, after bursa closed. If this is the case, we can expect a huge leap tomorrow, possibly a gap up.

KUALA LUMPUR (Nov 10): After posting a strong set of results for the third quarter ended Sept 30, 2020 (3QFY20), analysts expect Kossan Rubber Industries Bhd to record even stronger earnings for the next quarter (4QFY20), in tandem with rising average selling prices (ASPs) of gloves.

Net profit for the glove maker’s 3QFY20 surged 609% to RM348.74 million from RM49.18 million for the previous corresponding quarter, thanks to higher sales volume and selling prices as demand for rubber gloves continued to outstrip supply amid the Covid-19 pandemic.

Quarterly revenue jumped 95% to RM1.03 billion from RM531.26 million for 3QFY19. For the cumulative nine-month period ended Sept 30, 2020 (9MFY20), Kossan's net profit more than tripled to RM544.6 million from RM163.78 million for the year-ago period, while cumulative revenue grew 43% to RM2.35 billion from RM1.64 billion previously.

RHB Research Institute maintained its "buy" call for the stock with a higher target price (TP) of RM9, noting that the group’s expansion plans remain intact, with its capacity already up by 10% to 32 billion pieces per year, with a further addition of 1.5 billion pieces with the construction of Plant 20, which is due to be fully commissioned by the first half of 2021 (1H21).

The research house added that Kossan also stands a chance to join the FBM KLCI next month if it maintains its current market capitalisation of around RM17.6 billion.

“We increase our FY20-22 earnings [forecasts] by 91%-160% to reflect higher ASPs, in line with the industry trend. The higher TP is in line with better earnings estimates. In the near term, we expect Kossan to register a stronger set of results for 4QFY20, in line with the industry’s higher ASP trend. In the long run, Kossan is a beneficiary of a long-term global uptrend in glove consumption,” said RHB analyst Alan Lim.

Despite a strong set of results, the stock had fallen 8.27% or 62 sen to RM6.88 as at the time of writing today, in tandem with other glove counters which topped the loser list on Bursa Malaysia this morning as news of Pfizer’s Covid-19 vaccine candidate dominated the market’s optimism about ending the global pandemic and reopening the economy. Still, year to date, the stock has enjoyed a bull run with a 227% leap.

On another note, the fresh development of the potential vaccine could hamper Kossan’s share price in the near term, noted PublicInvest Research.

“Nonetheless, we think that it would still take about two years to have the entire global population vaccinated upon the roll-out of a vaccine, therefore any short-term price weakness would be an opportunity for investors to accumulate,” it said in a note today, upgrading its call for the stock to "trading buy" with a higher TP of RM9.40.

AmInvestment Bank, on the other hand, maintained its "hold" call for the stock with a lower fair value (FV) of RM7.07.

“We like Kossan as it is one of the biggest glove producers to benefit from the Covid-19 pandemic due to its expansionary plans and efforts in improving quality and operational efficiency. However, we believe that the stock is fully valued with a price-earnings ratio (PER) of 29 times [forecasted] FY22 earnings per share (EPS),” said AmInvestment Bank analyst Thong Pak Leng.

Thong noted that Kossan’s capacity had been fully taken up until end-2021, while still receiving orders for 2022.

“Around 10%-15% of its total capacity has been allocated for spot orders. Management indicated that incoming capacity will be directed to short-term orders,” he said.


TLDR: Don't panic if you hear about vaccine. Glove demand will always be high

NEW YORK (Reuters) - Work to distribute the experimental COVID-19 vaccine developed by Pfizer Inc and BioNTech SE is gearing up after the companies announced successful interim data earlier on Monday, but it will not be coming to local pharmacies for the general public any time soon.

The data, which sent U.S. stocks to record highs [.N], showed that the two companies’ experimental vaccine is 90% effective at preventing COVID-19. They are still awaiting data on safety, which could come later this month.

Pfizer and BioNTech need to get regulators to sign off on the shot before it can start shipping vaccines to those considered most in need by government. Healthcare workers and people living in nursing homes will likely top that list.

But the vaccine’s complex and super-cold storage requirements are an obstacle for even the most sophisticated hospitals in the United States and may impact when and where it is available in rural areas or poor countries where resources are tight.

The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius (-94 F) or below.

“The cold chain is going to be one of the most challenging aspects of delivery of this vaccination,” said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security.

“This will be a challenge in all settings because hospitals even in big cities do not have storage facilities for a vaccine at that ultra-low temperature.”

Indeed, one of the most prestigious U.S. hospitals, the Mayo Clinic in Rochester, Minnesota, said it does not currently have that capability.

“We’re talking about a vaccine that needs storage at minus 70 or 80. That’s a tremendous logistical issue not only in the U.S. but outside the Western world,” said Dr Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic.

“We’re a major medical center and we don’t have storage capacity like this. That will be true for everybody. This is a logistical obstacle.”

This is why I prefer long term investing over short term trading. In short term you are reactive to news, even rubbish news. vaccine news? glove counters drop. Which doesn't make sense

By modern health standards to administer vaccine to you need 1 pair of gloves per patient. To vaccinate the entire world would take years. So gloves demand will be really high for at least next 2-3 years.

This is also why the glove companies are not afraid to expand their current capacity regardless of vaccine news. Their sales is not affected by vaccine.

Non glove company like Mahsing needs at least 1 year to start producing gloves but they still do it. Not afraid of new vaccines during that period meh?

If you panic from any kind of news, better take out your money and put it in somewhere like mutual funds. Stock market is not for you. Especially Malaysian stock market where companies that have great QR can see their price fall the following day

Remember the basics. Buying stocks is buying part of a company. If the company makes money, you will make money

Plus, opposition are advocating for decreased budget for certain areas and putting that money to tackle covid and rakyat's welfare. Gov allocated money for hc. opposition want MORE money for hc

Either way, hc counters win

Parliament session right now. Debating about the budget. Traders are being careful.

But with everything going on, there will be still a very strong push for hc counters.

All the requirements for careplus to fly have been met
[✓] CMCO
[✓] 2021 Budget
[✓] Biden victory
[✓] No windfall tax
[✓] Directors buying shares
[✓] Stellar QR

Can easily fly beyond RM4. You will be foolish to sell lower than RM4

Georgia just turned from pink to light blue
Biden's lead in Nevada is getting bigger

Biden is almost guaranteed to win. Budget + Biden's win will be massive boost for hc counters next week.

Carepls bonus issue record

Jul 2011 1:2
Jul 2015 1:2

Based on this, another one might not be far away

Let's face it. The biggest issue with this country right now is covid. What do you think will take priority for next year's budget? HANDLING COVID

Boost for healthcare sectors as well as construction and communication (5G infra).

After announcement, it's very likely for carepls to go beyond RM4. Add that with Biden's to be confirmed victory, can easily reach 4.5. You will be foolish to sell at any price below RM4

Too many noobs buy carepls. Good performing company, strong fundamentals, lowest PE among glove counters. But when price fluctuates a little bit, all the noobs panic sell and push the price lower, losing money in the process.

regardless who wins US election, regardless what happens to budget, regardless of covid vaccine, there will be guaranteed high demand for gloves until at least end of 2021.

Noobs, play stock, heart must be strong. If so easily panic better put your money in public mutual

People have committed suicide because lost money in stocks. someone else losing money is no laughing matter. Have respect for everyone. We all trying to make money here

Many investors are so confused and did not know what to do. Some novice even sold their holdings and thought they were so clever. Some short-term day traders bought and sold to make some small sums of money. But statistics shows that 80% are losers, 10% break even and only 10% of the people are winners in the stock market. Day traders are in the 80% group.

In fact, under the current Covid 19 pandemic, the number of losers can even more than 80% because the pandemic is affecting everyone’s movement and all the listed companies except medical gloves and medical products for the virus prevention. Out of 1,100 listed companies, the total number of glove stocks and medical products can be counted with your fingers. That is why all the Investment Banks are losers because they have to hold many stocks to spread their investment risk. Investors who do not have glove stocks in their portfolio should get their head examined and those who want to sell must be really stupid.

KYY

Careplus is the manufacturer. Ansell is the distributor. If manufacturers can sell their own goods themselves, supermarkets wouldn't exist